Glutamate and Parkinson's disease

Fabio Blandini, Richard H P Porter, J. Timothy Greenamyre

Research output: Contribution to journalArticle

243 Citations (Scopus)

Abstract

Altered glutamatergic neurotransmission and neuronal metabolic dysfunction appear to be central to the pathophysiology of Parkinson's disease (PD). The substantia nigra pars compacta-the area where the primary pathological lesion is located-is particularly exposed to oxidative stress and toxic and metabolic insults. A reduced capacity to cope with metabolic demands, possibly related to impaired mitochondrial function, may render nigral neurons highly vulnerable to the effects of glutamate, which acts as a neurotoxin in the presence of impaired cellular energy metabolism. In this way, glutamate may participate in the pathogenesis of PD. Degeneration of dopamine nigral neurons is followed by striatal dopaminergic denervation, which causes a cascade of functional modifications in the activity of basal ganglia nuclei. As an excitatory neurotransmitter, glutamate plays a pivotal role in normal basal ganglia circuitry. With nigrostriatal dopaminergic depletion, the glutamatergic projections from subthalamic nucleus to the basal ganglia output nuclei become overactive and there are regulatory changes in glutamate receptors in these regions. There is also evidence of increased glutamatergic activity in the striatum. In animal models, blockade of glutamate receptors ameliorates the motor manifestations of PD. Therefore, it appears that abnormal patterns of glutamatergic neurotransmission are important in the symptoms of PD. The involvement of the glutamatergic system in the pathogenesis and symptomatology of PD provides potential new targets for therapeutic intervention in this neuro-degenerative disorder.

Original languageEnglish
Pages (from-to)73-94
Number of pages22
JournalMolecular Neurobiology
Volume12
Issue number1
DOIs
Publication statusPublished - Feb 1996

Fingerprint

Parkinson Disease
Glutamic Acid
Basal Ganglia
Glutamate Receptors
Substantia Nigra
Synaptic Transmission
Corpus Striatum
Subthalamic Nucleus
Poisons
Dopaminergic Neurons
Neurotoxins
Denervation
Energy Metabolism
Neurotransmitter Agents
Oxidative Stress
Animal Models
Neurons
Therapeutics

Keywords

  • Basal ganglia
  • bioenergetics
  • excitatory amino acids
  • excitotoxicity
  • N-methyl-D-aspartate

ASJC Scopus subject areas

  • Cellular and Molecular Neuroscience
  • Neuroscience(all)
  • Physiology

Cite this

Glutamate and Parkinson's disease. / Blandini, Fabio; Porter, Richard H P; Greenamyre, J. Timothy.

In: Molecular Neurobiology, Vol. 12, No. 1, 02.1996, p. 73-94.

Research output: Contribution to journalArticle

Blandini, F, Porter, RHP & Greenamyre, JT 1996, 'Glutamate and Parkinson's disease', Molecular Neurobiology, vol. 12, no. 1, pp. 73-94. https://doi.org/10.1007/BF02740748
Blandini, Fabio ; Porter, Richard H P ; Greenamyre, J. Timothy. / Glutamate and Parkinson's disease. In: Molecular Neurobiology. 1996 ; Vol. 12, No. 1. pp. 73-94.
@article{9c7d2d90df684599b95a02da1a71a17a,
title = "Glutamate and Parkinson's disease",
abstract = "Altered glutamatergic neurotransmission and neuronal metabolic dysfunction appear to be central to the pathophysiology of Parkinson's disease (PD). The substantia nigra pars compacta-the area where the primary pathological lesion is located-is particularly exposed to oxidative stress and toxic and metabolic insults. A reduced capacity to cope with metabolic demands, possibly related to impaired mitochondrial function, may render nigral neurons highly vulnerable to the effects of glutamate, which acts as a neurotoxin in the presence of impaired cellular energy metabolism. In this way, glutamate may participate in the pathogenesis of PD. Degeneration of dopamine nigral neurons is followed by striatal dopaminergic denervation, which causes a cascade of functional modifications in the activity of basal ganglia nuclei. As an excitatory neurotransmitter, glutamate plays a pivotal role in normal basal ganglia circuitry. With nigrostriatal dopaminergic depletion, the glutamatergic projections from subthalamic nucleus to the basal ganglia output nuclei become overactive and there are regulatory changes in glutamate receptors in these regions. There is also evidence of increased glutamatergic activity in the striatum. In animal models, blockade of glutamate receptors ameliorates the motor manifestations of PD. Therefore, it appears that abnormal patterns of glutamatergic neurotransmission are important in the symptoms of PD. The involvement of the glutamatergic system in the pathogenesis and symptomatology of PD provides potential new targets for therapeutic intervention in this neuro-degenerative disorder.",
keywords = "Basal ganglia, bioenergetics, excitatory amino acids, excitotoxicity, N-methyl-D-aspartate",
author = "Fabio Blandini and Porter, {Richard H P} and Greenamyre, {J. Timothy}",
year = "1996",
month = "2",
doi = "10.1007/BF02740748",
language = "English",
volume = "12",
pages = "73--94",
journal = "Molecular Neurobiology",
issn = "0893-7648",
publisher = "Humana Press Inc.",
number = "1",

}

TY - JOUR

T1 - Glutamate and Parkinson's disease

AU - Blandini, Fabio

AU - Porter, Richard H P

AU - Greenamyre, J. Timothy

PY - 1996/2

Y1 - 1996/2

N2 - Altered glutamatergic neurotransmission and neuronal metabolic dysfunction appear to be central to the pathophysiology of Parkinson's disease (PD). The substantia nigra pars compacta-the area where the primary pathological lesion is located-is particularly exposed to oxidative stress and toxic and metabolic insults. A reduced capacity to cope with metabolic demands, possibly related to impaired mitochondrial function, may render nigral neurons highly vulnerable to the effects of glutamate, which acts as a neurotoxin in the presence of impaired cellular energy metabolism. In this way, glutamate may participate in the pathogenesis of PD. Degeneration of dopamine nigral neurons is followed by striatal dopaminergic denervation, which causes a cascade of functional modifications in the activity of basal ganglia nuclei. As an excitatory neurotransmitter, glutamate plays a pivotal role in normal basal ganglia circuitry. With nigrostriatal dopaminergic depletion, the glutamatergic projections from subthalamic nucleus to the basal ganglia output nuclei become overactive and there are regulatory changes in glutamate receptors in these regions. There is also evidence of increased glutamatergic activity in the striatum. In animal models, blockade of glutamate receptors ameliorates the motor manifestations of PD. Therefore, it appears that abnormal patterns of glutamatergic neurotransmission are important in the symptoms of PD. The involvement of the glutamatergic system in the pathogenesis and symptomatology of PD provides potential new targets for therapeutic intervention in this neuro-degenerative disorder.

AB - Altered glutamatergic neurotransmission and neuronal metabolic dysfunction appear to be central to the pathophysiology of Parkinson's disease (PD). The substantia nigra pars compacta-the area where the primary pathological lesion is located-is particularly exposed to oxidative stress and toxic and metabolic insults. A reduced capacity to cope with metabolic demands, possibly related to impaired mitochondrial function, may render nigral neurons highly vulnerable to the effects of glutamate, which acts as a neurotoxin in the presence of impaired cellular energy metabolism. In this way, glutamate may participate in the pathogenesis of PD. Degeneration of dopamine nigral neurons is followed by striatal dopaminergic denervation, which causes a cascade of functional modifications in the activity of basal ganglia nuclei. As an excitatory neurotransmitter, glutamate plays a pivotal role in normal basal ganglia circuitry. With nigrostriatal dopaminergic depletion, the glutamatergic projections from subthalamic nucleus to the basal ganglia output nuclei become overactive and there are regulatory changes in glutamate receptors in these regions. There is also evidence of increased glutamatergic activity in the striatum. In animal models, blockade of glutamate receptors ameliorates the motor manifestations of PD. Therefore, it appears that abnormal patterns of glutamatergic neurotransmission are important in the symptoms of PD. The involvement of the glutamatergic system in the pathogenesis and symptomatology of PD provides potential new targets for therapeutic intervention in this neuro-degenerative disorder.

KW - Basal ganglia

KW - bioenergetics

KW - excitatory amino acids

KW - excitotoxicity

KW - N-methyl-D-aspartate

UR - http://www.scopus.com/inward/record.url?scp=0030080245&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030080245&partnerID=8YFLogxK

U2 - 10.1007/BF02740748

DO - 10.1007/BF02740748

M3 - Article

C2 - 8732541

AN - SCOPUS:0030080245

VL - 12

SP - 73

EP - 94

JO - Molecular Neurobiology

JF - Molecular Neurobiology

SN - 0893-7648

IS - 1

ER -